What's Happening?
A new analysis published in Epigenetics Communications indicates that long-term aspirin use is associated with a measurable deceleration of epigenetic mitotic clocks in healthy colon tissue. This finding, derived from a decade-long follow-up study of Polish
women, offers insights into how aspirin may protect against colorectal cancer, one of the most common cancers globally. Epigenetic clocks are mathematical models that estimate biological age by analyzing DNA methylation patterns, which are chemical tags that influence gene activity. Mitotic clocks, specifically EpiTOC, EpiTOC2, and MiAge, are designed to estimate the cumulative number of cell divisions a tissue has undergone. The study found that in the proximal colon of long-term aspirin users, the intrinsic rates of all three mitotic clocks significantly decelerated over a ten-year period. This deceleration was not observed in non-users. In the distal colon, only the MiAge clock showed significant deceleration among long-term users. The research involved analyzing DNA methylation profiles from healthy colon mucosa biopsies collected at two timepoints from 28 Polish women, 17 of whom were long-term aspirin users.
Why It's Important?
This research is important because it provides a potential mechanism for aspirin's known chemopreventive effects against colorectal cancer. Colorectal cancer is the third most frequently diagnosed cancer worldwide, and randomized controlled trials have already shown aspirin's ability to reduce its incidence in certain populations. The United States Preventive Services Task Force recommends low-dose aspirin for primary prevention in adults aged 50 to 59 with at least a 10 percent ten-year cardiovascular disease risk. By demonstrating that aspirin can slow down cellular aging processes in the colon, this study strengthens the scientific basis for these recommendations and highlights the potential for epigenetic aging measures as novel biomarkers for earlier and more precise cancer risk detection. The observed difference in effect between the proximal and distal colon is also significant, as these regions differ in their embryonic origin and molecular pathways for tumor initiation, suggesting that future studies should consider colon location-specific results. This could lead to more targeted and effective prevention strategies.
What's Next?
The study's authors recommend that future colorectal cancer epigenetic studies include both traditional epigenetic age measures (Hannum, Horvath, and PhenoAge) and mitotic clocks (MiAge, EpiTOC, and EpiTOC2) to standardize the field and enable meaningful meta-analyses. While the current study was observational and involved a limited sample size of Polish women, larger, more diverse, and prospective trials are needed to establish causality and confirm these findings across different populations. Researchers also emphasize the need to explicitly distinguish the effects of racism and social environment from ancestry in epigenetic aging studies, given the documented racial disparities in colorectal cancer and the links between epigenetic aging and social factors. Further research will also need to investigate the optimal aspirin dosage and long-term adherence, as well as potential contraindications, to translate these findings into broader clinical practice.
Beyond the Headlines
Beyond the immediate implications for colorectal cancer prevention, this study contributes to a deeper understanding of the complex interplay between lifestyle interventions, cellular aging, and disease development. The finding that a common, inexpensive drug like aspirin can influence epigenetic clocks underscores the potential for existing medications to have broader health benefits than previously understood. It also highlights the growing importance of epigenetics in personalized medicine, where understanding individual methylation patterns could lead to tailored prevention and treatment strategies. The caution urged by researchers regarding the social dimensions of epigenetic aging points to the ethical and societal considerations that must accompany advancements in this field, ensuring that new biomarkers and interventions do not exacerbate existing health disparities but rather contribute to equitable health outcomes. This research also sets a precedent for using advanced sequencing-based methylation profiling to uncover disease-associated regions that might be missed by conventional methods, potentially revolutionizing early detection for various cancers and diseases.
